FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots - FDA Press Releases

The FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.

from FDA Press Releases RSS Feed http://bit.ly/2JMdfTE
via IFTTT